Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals by Eminzade, Sude et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
Nutrition & Metabolism
Open Access Research
Silymarin protects liver against toxic effects of anti-tuberculosis 
drugs in experimental animals
Sude Eminzade*1, Fikriye Uras2 and Fikret V Izzettin1
Address: 1Department of Pharmacology, Marmara University, Faculty of Pharmacy, Haydarpasa, Istanbul, Turkey and 2Department of 
Biochemistry, Marmara University, Faculty of Pharmacy, Haydarpasa, Istanbul, Turkey
Email: Sude Eminzade* - seminzade@hotmail.com; Fikriye Uras - furas@marmara.edu.tr; Fikret V Izzettin - fvizzettin@klinikecza.org
* Corresponding author    
Abstract
Background:  The first line anti-tuberculosis drugs isoniazid (INH), rifampicin (RIF) and
pyrazinamide (PZA) continues to be the effective drugs in the treatment of tuberculosis, however,
the use of these drugs is associated with toxic reactions in tissues, particularly in the liver, leading
to hepatitis. Silymarin, a standard plant extract with strong antioxidant activity obtained from S.
marianum, is known to be an effective agent for liver protection and liver regeneration. The aim of
this study was to investigate the protective actions of silymarin against hepatotoxicity caused by
different combinations of anti-tuberculosis drugs.
Methods: Male Wistar albino rats weighing 250–300 g were used to form 6 study groups, each
group consisting of 10 rats. Animals were treated with intra-peritoneal injection of isoniazid (50
mg/kg) and rifampicin (100 mg/kg); and intra-gastric administration of pyrazinamid (350 mg/kg) and
silymarin (200 mg/kg). Hepatotoxicity was induced by a combination of drugs with INH+RIF and
INH+RIF+PZA. Hepatoprotective effect of silymarin was investigated by co-administration of
silymarin together with the drugs. Serum biochemical tests for liver functions and histopathological
examination of livers were carried out to demonstrate the protection of liver against anti-
tuberculosis drugs by silymarin.
Results: Treatment of rats with INH+RIF or INH+RIF+PZA induced hepatotoxicity as evidenced
by biochemical measurements: serum alanine aminotransferase (ALT), aspartate aminotransferase
(AST) and alkaline phosphatase (ALP) activities and the levels of total bilirubin were elevated, and
the levels of albumin and total protein were decreased in drugs-treated animals. Histopathological
changes were also observed in livers of animals that received drugs. Simultaneous administration
of silymarin significantly decreased the biochemical and histological changes induced by the drugs.
Conclusion:  The active components of silymarin had protective effects against hepatotoxic
actions of drugs used in the chemotherapy of tuberculosis in animal models. Since no significant
toxicity of silymarin is reported in human studies, this plant extract can be used as a dietary
supplement by patients taking anti-tuberculosis medications.
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Background
Rifampicin (RIF), isoniazid (INH), pyrazinamid (PZA)
and ethambutol are first line drugs used for the treatment
of tuberculosis. Rifampicin has bactericidal activity
against  M. tuberculosis by inhibiting bacterial DNA-
dependent RNA polymerase [1]. Isoniazid is a prodrug
activated by bacterial catalase-peroxidase (KatG) and kills
actively growing tubercle bacilli by inhibiting the biosyn-
thesis of mycolic acids which are major components of
cell wall of M. tuberculosis [1,2]. The other prodrug, pyrazi-
namid, is activated by bacterial pyrazinamidinase which is
only active in acidic conditions (pH: 5.5). The active
metabolite is pyrazinoic acid that inhibits fatty acid syn-
thesis in M. tuberculosis [3]. This drug is used in the initial
two months of treatment to reduce the duration of ther-
apy, and is not used alone [4]. Ethambutol inhibits the
synthesis of some metabolites in actively growing M.
tuberculosis, causing impairment of cell metabolism, arrest
of multiplication, and cell death [5].
Drugs are not used solely in the treatment of tuberculosis.
Instead, the first line drugs are used in combination, or
with other medicines. The single use of drug may result in
the rapid development of resistance or failure of treat-
ment. Several regimens are available for the treatment of
tuberculosis. Depending on the duration of treatment or
in the case of resistance, individual drugs may be omitted
from the protocol. Several adverse reactions of anti-tuber-
culosis drugs are reported. The best known toxic drug
effect is hepatotoxicity. The frequency and severity of
hepatotoxicity is increased when these drugs are used in
combination [1,4,6]. Anti-tuberculosis drugs act as induc-
ers of hepatic cytochrome P450 enzymes. For example,
rifampicin is a potent inducer of CYP2D6 and CYP3A4,
and isoniazid induces CYP2E1 [6,7]. The induction of
CYT P450 enzymes is known to take part in increased drug
disposition and development of multi-drug resistance.
Xenobiotics, including anti-tuberculosis drugs, undergo
biotransformation in the liver catalyzed by microsomal
enzyme systems. The major isozyme of cytochrom P450
enzymes in bioactivation is CYT2E1, which is also
involved in hepatic toxicity of carbon tetrachloride, etha-
nol and acetaminophen. Inhibition of this isozyme by
specific inhibitors or herbal drugs has been shown to be
hepatoprotective [8-10]. Several reactive derivatives of
drugs and oxidants are generated during the process of
drug biotransformation. The reactive species generated
can bind and/or react with cellular components in the
liver, and cause liver injury resulting in impairment of
liver functions. Reaction of reactive species with cellular
antioxidants causes antioxidant depletion that may result
in oxidative stress [9,11,12].
Recent studies indicate the existence of a strong correla-
tion between hepatic injury and oxidant stress in experi-
mental animals treated with anti-tuberculosis drugs [8,12-
17]. Since all the drugs used in the treatment of tubercu-
losis are shown to have hepatotoxic effects, studies have
been performed to prevent or reduce the toxicity by the
use of natural herbal drugs and/or synthetic compounds,
without interfering with the therapeutic actions of the
drugs. Garlic [14], silymarin, [12,15] N-acetylcysteine
[16,17] and several other herbal drugs are proved to have
such effects. It is of importance to note that the inhibition
of CYTP450 2E1 and antioxidant actions seem to be the
common mechanism of action of herbal drugs [9-15].
Among the herbal drugs, silymarin has been used as a die-
tary supplement for hepatoprotection for over 2000 years.
Silymarin, commercially avaible as Milk Thistle, is an
extract from the seeds of S. Marianum. Silybines (A and B
isomers), isosilybines (A and B), silychristine and sily-
dianine are active flavonoids found in silymarin extract
[18]. Silymarin has been shown to be safe in animal mod-
els, and no significant adverse reactions are reported in
human studies [18]. In this study, we researched the
hepatoprotective effects of silymarin in rats treated with
two different combinations of antituberculosis drugs iso-
niazid, rifampicin and pyrazinamid.
Methods
Animals
Male Wistar albino rats weighing about 250–300 g were
selected and used in the present study. All experiments
were carried out according to the guidelines for the care
and use of experimental animals, and approved by the
Animals Ethical Committee of Marmara University Fac-
ulty of Medicine. Rats were acclimatized for 2 weeks
before starting the experiments. Animals were maintained
in a 12 h light/dark cycle at 25°C and were free access to
standard pellet food and tap water. One way variance
analysis showed no significant difference between the
mean weight of animals at the beginning of the treatment
(mean weight of each group was 275 g with a standard
deviation of 13). Intake of feed and water was observed
and assessed for all the animals during the treatment.
Drugs and Chemicals
The first line anti-tuberculosis drugs used in the study
were isoniazid (from ZheJiang TaiZhou JiangBei chemical
factory), rifampicin (CKD Bio Corporation) and pyrazin-
amid (Koçak Medicinal Industry). Milk Thistle (sily-
marin) was purchased from Solgar. Other chemicals used
in the study were of analytic grade. Isoniazid and
rifampicin were separately dissolved in sterile distilled
water. Because of poor solubility, suspensions of pyrazin-
amid and silymarin were prepared for intra-gastric admin-
istration [19].Nutrition & Metabolism 2008, 5:18 http://www.nutritionandmetabolism.com/content/5/1/18
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Animal Study Protocol
Sixty animals used in this study were divided into six
groups. Blood samples were taken from the tail vein of
each animal to evaluate liver functions before the treat-
ment. The first group (Group I) served as the control
group, and was intra-peritonealy injected with sterile
saline (1 ml/kg). The second group (Group II) was sily-
marin-control group that received intra-gastric adminis-
tration of silymarin suspension at a dose of 200 mg/kg
(silymarin suspension was prepared by suspending the
content of Milk Thistle gelatin capsules in sterile distilled
water). The third (Group III) and fourth (Gourp IV)
groups were hepatotoxicity model groups that were intra-
peritoneally injected with isoniazid (50 mg/kg) and
rifampicin (100 mg/kg) [12,13,16,20]. The fourth group
of animals received 350 mg/kg pyrazinamid via intra gas-
tric route in addition to isoniazid and rifampicin. The fifth
(group V) and sixth (Group VI) groups received the same
drugs at the same doses as given for Group III and Group
IV, respectively; except that the last two groups were
treated additionally with intra-gastric administration of
silymarin at a dose of 200 mg/kg. Drugs were given once
daily according to the above protocol over 14 days. One
day after the last treatment, body weights were recorded,
and animals were anesthesized with intra-peritoneal
injection of high dose ketamin. Blood was obtained by
cardiac puncture immediately, and livers were saved for
histopathological examination.
Biochemical Assessments
The liver is the site of bilirubin detoxification and excre-
tion. Several plasma proteins, including albumin, are syn-
thesized in the liver, and the liver also regulates plasma
lipids and lipoproteins. Therefore, the levels of albumin,
total protein and bilirubin can be used as indicators of
liver function. Serum ALT, AST and ALP activities are con-
sidered as good markers of hepatic injury and hepatocel-
lular integrity. We measured the activities of these
enzymes before starting the treatment (as baseline values)
and after the treatment of rats with the drugs.
Blood samples obtained either from tail vein (before treat-
ments) or cardiac puncture (after the treatment) were cen-
trifuged and serum samples were stored in a deep freezer
until they could be analyzed. Serum alanine aminotrans-
ferase (ALT), aspartate aminotransferase (AST), alkaline
phosphatase (ALP) activities and the levels of serum albu-
min, serum total protein, and serum total bilirubin were
determined by Hitachi-917 auto-analyzer using kits man-
ufactured by Roche Diagnostic Division.
Histopathological Investigation
Small pieces of liver tissues from animals were preserved
in 10% formaldehyde, and later were embedded into par-
affin blocks. Thin sections (5 μM) were prepared from the
blocks for microscopic examination. Light microscopy
was performed after slides were routinely stained with
haematoxylin and eosin (H&E).
Statistical Analysis
In biochemical determinations, each sample was assayed
in duplicate, and average values were calculated as means
plus or minus standard deviation (SD). Data were ana-
lyzed by one-way analysis of variance (ANOVA), followed
by multiple comparisons using Dunnett's procedure to
compare all groups against control. Unpaired Student t
testing was also used to assess differences between groups.
A P value of less than 0.05 was considered statistically sig-
nificant.
Results
Before the initiation of the drug treatment, baseline liver
function tests were performed and any animal with
abnormal liver function test was excluded from the study.
Water and food intake was the same in all groups and no
mortality was observed throughout the study. Body
weights were increased in all groups as compared with the
weights before the treatment. However, no significant dif-
ference in body weights was observed between the groups.
Similar results are reported in earlier studies [1,2].
We measured the activities of ALT, AST and ALP before
starting the treatment (as baseline values) and after the
treatment of rats with the drugs. The serum ALT, AST and
ALP activities of the control group (group I) and the sily-
marin-control group (group II) did not show any signifi-
cant difference when compared with baseline values
(Figures 1, 2, 3). However, treatment of rats with INH +
RIF (group III) or with INH + RIF + PZA (group IV) caused
a 2 fold increase (P < 0.001) from their baseline of ALT
(Figure 1). The activities of serum AST and ALP were also
increased (P < 0.001) approximately 75% in drugs-treated
animals, indicating that the drugs had caused a decrease
in hepatocellular integrity (Figures 2 and 3). Pyrazina-
mide did not seem to exacerbate the hepatotoxic actions
of INH and RIF when serum enzyme activities are evalu-
ated (Figures 1, 2, 3, P > 0.05).
Simultaneous intra-gastric administration of silymarin
with anti-tuberculosis drugs either with INH + RIF (group
V) or INH + RIF + PZA (group VI) significantly decreased
(P < 0.001) the serum enzyme activities when compared
with hepatotoxicity groups (Groups III and IV).
We measured serum albumin, total protein and total
bilirubin levels in rats before and after the treatment with
the drugs. Treatment of rats with INH + RIF or INH + RIF
+ PZA significantly decreased (P < 0.001) serum albumin
and total protein concentrations and caused a 2 fold
increase in total bilirubin levels (Tables 1 and 2). No sig-Nutrition & Metabolism 2008, 5:18 http://www.nutritionandmetabolism.com/content/5/1/18
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nificant difference was found between group III and group
IV, indicating that PZA did not aggravate the toxic effects
of INH and RIF. Co-administration of silymarin with INH
+ RIF or with INH + RIF + PZA significantly increased
serum albumin and total protein concentrations and
decreased serum total bilirubin levels when compared
with rat groups that received drugs only (groups III and
IV) (P  < 0.001). However, drugs and silymarin-treated
groups still had lower albumin and total protein, and
higher total bilirubin levels when compared with the con-
trol (P < 0.01), except that total protein of group VI was
not different from that of control (Table 2).
Light microscopic histological evaluation of liver tissues is
given in Table 3. The control and the silymarin group ani-
mals had normal liver histology. Liver degeneration was
observed in all animals from groups III and IV. In group V
and VI, 6 out of 10 rats had degenerated liver. Steatosis
and patchy necrosis was detected in hepatotoxicity groups
(Groups III and IV), and the frequency of both steatosis
and patchy necrosis was decreased by silymarin adminis-
tration. Portal triaditis was detected in group III and group
IV, which were not detectable in groups receiving drugs
plus silymarin (groups V and VI). Despite earlier findings
[2], we did not observe any fibrosis or regeneration in the
liver of any rat (Table 3).
Discussion
Tuberculosis is a leading public health problem world
wide, particularly in developing countries. About one
Serum ALT activities of rats before and after treatment with anti-tuberculosis drugs and silymarin Figure 1
Serum ALT activities of rats before and after treatment with anti-tuberculosis drugs and silymarin. Constant 
doses of INH (50 mg/kg), RIF (100 mg/kg), PZA (350 mg/kg) and silymarin (200 mg/kg) were used. Group I: Control, Group II: 
Silymarin control, Group III: INH+RIF, Group IV: INH+RIF+PZA, Group V: INH+RIF+Silymarin, and Group VI: 
INH+RIF+PZA+Silymarin. * P < 0.001 as compared with groups I, II, V and VI. * P < 0.05 as compared with Groups I and II.Nutrition & Metabolism 2008, 5:18 http://www.nutritionandmetabolism.com/content/5/1/18
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third of world's population has latent tuberculosis and
approximately 9 million cases of active tuberculosis
emerge annually resulting in 2–3 million deaths [20]. Out
of 1.86 billion people estimated to be infected with the
tuberculosis bacillus, an estimated 1.3 billion infected
people were living in developing countries, such as India
and China [21]). In view of the seriousness of the problem
World Health Organization (WHO) declared it to be a
global emergency in 1993. Active tuberculosis will kill
about two out of every three people if untreated. Even
treated tuberculosis has a mortality rate of just less than
5% [22]. Anti-tuberculosis drugs are used in combination,
except in latent tuberculosis or chemoprophylaxis. The
use of INH and RIF is associated with hepatotoxicity in
some individuals. The rate of hepatotoxicity is much
higher in developing countries like India (8%–30%) com-
pared to that in advanced countries [23,24].
Rats have been used successfully to investigate INH and
RIF-induced hepatotoxicity models [4,12-17]. Therefore,
we selected rats to study the hepatotoxic effect of anti-
tuberculosis drugs and hepatoprotective action of sily-
marin. In the present study, hepatotoxicity was produced
by daily co-administration of INH+RIF or INH+ RIF+PZA
over 14 days. Since hepatotoxic action of INH and RIF is
well documented [11-13,16,17,20,25], instead of single
use of drugs, we treated the animals with two different
combinations as done in the treatment of tuberculosis.
The doses of the drugs used (INH: 50 mg/kg, RIF: 100 mg/
kg and PZA: 350 mg/kg) are very high compared to those
Serum AST activities of rats before and after treatment with anti-tuberculosis drugs and silymarin Figure 2
Serum AST activities of rats before and after treatment with anti-tuberculosis drugs and silymarin. Constant 
doses of INH (50 mg/kg), RIF (100 mg/kg), PZA (350 mg/kg) and silymarin (200 mg/kg) were used. Group I: Control, Group II: 
Silymarin control, Group III: INH+RIF, Group IV: INH+RIF+PZA, Group V: INH+RIF+Silymarin, and Group VI: 
INH+RIF+PZA+Silymarin. * P < 0.001 as compared with groups I, II, V and VI. * P < 0.05 as compared with Groups I and II.Nutrition & Metabolism 2008, 5:18 http://www.nutritionandmetabolism.com/content/5/1/18
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used in the treatment of tuberculosis in human subjects.
However, higher doses of drugs are required in animal
models to produce hepatotoxicity, because rats metabo-
lize the drugs at a faster rate and the duration of treatment
is much shorter compared to the treatment of tuberculosis
in humans.
Biochemical tests related to the hepatocellular integrity
can be checked to follow hepatocellular integrity and liver
injury. In this study, the injection of INH and RIF caused
a significant elevation (approximately 2 fold increase) in
the activities of ALT, AST and ALP. Increased activity of
these enzymes showed that the integrity of hepatocytes
Serum ALP activities of rats before and after treatment with anti-tuberculosis drugs and silymarin Figure 3
Serum ALP activities of rats before and after treatment with anti-tuberculosis drugs and silymarin. Constant 
doses of INH (50 mg/kg), RIF (100 mg/kg), PZA (350 mg/kg) and silymarin (200 mg/kg) were used. Group I: Control, Group II: 
Silymarin control, Group III: INH+RIF, Group IV: INH+RIF+PZA, Group V: INH+RIF+Silymarin, and Group VI: 
INH+RIF+PZA+Silymarin. * P < 0.001 as compared with groups I, II, V and VI. * P < 0.05 as compared with Groups I and II.
Table 1: Baseline levels of serum albumin, total protein and bilirubin in rats before treatment with anti-tuberculosis drugs.
Groups Albumin (gr/dl) Total protein (gr/dl) Total bilirubin (mg/dl)
I (control) 4.51 ± 0.30 7.56 ± 0.43 0.077 ± 0.015
II (silymarin control) 4.65 ± 0.37 7.89 ± 0.41 0.080 ± 0.014
III (INH+RIF) 4.57 ± 0.33 7.81 ± 0.33 0.086 ± 0.016
IV (INH+RIF+PZA) 4.75 ± 0.32 7.78 ± 0.58 0.085 ± 0.019
V (INH+RIF + Silymarin) 4.73 ± 0.38 7.70 ± 0.56 0.077 ± 0.018
VI (INH+RIF+PZA+Silymarin) 4.47 ± 0.31 7.66 ± 0.31 0.096 ± 0.017
Values represent mean ± SD.Nutrition & Metabolism 2008, 5:18 http://www.nutritionandmetabolism.com/content/5/1/18
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was abnormal, resulting in the release of intracellular
enzymes into the systemic circulation (Figures 1, 2, 3).
Much higher activities of these enzymes is measured in
serum when rats are treated with INH and RIF over longer
period, up to 90 days [26]. Serum total bilirubin was also
increased two fold, indicating membrane damage in the
liver (Table 2). Decrease in albumin and total protein lev-
els showed that administration of drugs has caused
impairment of liver function, e.g. its capacity to synthesize
albumin (Table 2). Histopathological changes observed
in drugs-treated animals correlated well with biochemical
results (Table 3). Based on in vivo and in vitro results, it is
suggested that the underlying mechanism for hepatotoxic-
ity is related to: 1) drug bioactivation by CYTP450 2E1, 2)
generation of oxygen free radicals and reactive metabo-
lites of drugs, 3) imbalance in the oxidant/antioxidant
defense, and 4) eventual peroxidation of membrane lipids
that leads to the loss of hepatocellular integrity and failure
of liver function. In the present study, inclusion of PZA to
the treatment protocol (Group IV) did not further
enhance the hepatotoxicity of INH and RIF (Table 4). This
result is consistent with earlier observation that PZA did
not promote lipid peroxidation, and has no effect on anti-
oxidant status in the liver, either when is used alone or
with INH and/or RIF [26].
The available literature shows that the extracts obtained
from several plants have hepatoprotective activities
against the toxicity induced by xenobiotics, including
those that are used in the treatment of tuberculosis
[12,14,19,21,27,28]. Silymarin, the root extract from Sily-
bum marianum, is known to have such an activity. In this
study, the administration of silymarin together with
INH+RIF or INH+RIF+PZA decreased hepatotoxicity of
drugs as judged from liver function tests. Silymarin
decreased serum ALT, AST and ALP activities, and the lev-
els of bilirubin; increased serum albumin and total pro-
tein concentration in drugs-treated animals. The serum
ALT, AST and ALP activities of the control group (group I)
and the silymarin-control group (group II) did not show
any significant difference when compared with baseline
values. This showed that silymarin has no significant
undesired actions on hepatocellular integrity on its own.
However, silymarin did not have a complete protection
against drug toxicity, since groups V and VI still had higher
serum enzyme activities when compared with the controls
(P < 0.05) (Figures 1, 2, 3).
Silymarin administration significantly reduced the
number of animals with pathological liver changes, and
the severity of changes were less, if any, compared to the
hepatotoxicity groups. Consistent with previous studies,
these results clearly show that silymarin has protective
effects towards the toxic actions of anti-tuberculosis drugs
[12,19]. Recently, several studies have been carried out to
elucidate the mechanism of action of silymarin. Accumu-
lated data show that this herbal drug inhibits several iso-
forms of CYT P450 enzymes [7-10], potentiates the
antioxidant capacity of the liver [20], acts as a scavenger of
oxygen free radicals [29], inhibits the synthesis of proin-
Table 2: The levels of albumin, total protein and total bilirubin after the treatment of rats with antituberculosis drugs and silymarin.
Groups Albumin (gr/dl) Total Protein (gr/dl) Total Bilirubin (mg/dl)
I (control) 4.20 ± 0.40 7.27 ± 0.32 0.095 ± 0.022
II (silymarin control) 4.42 ± 0.40 7.49 ± 0.34 0.099 ± 0.021
III (INH+RIF) 3.44 ± 0.32* 5.80 ± 0.59* 0.194 ± 0.052*
IV (INH+RIF+PZA) 3.35 ± 0.17* 5.70 ± 0.48* 0.199 ± 0.049*
V (INH+RIF+Silymarin) 4.02 ± 0.28** 6.84 ± 0.41** 0.118 ± 0.036**
VI (INH+RIF+PZA+Silymarin) 3.95 ± 0.47*** 6.85 ± 0.59** 0.137 ± 0.026**
Values represent mean ± SD. Constant doses of INH (50 mg/kg), RIF (100 mg/kg), PZA (350 mg/kg) and silymarin (200 mg/kg) were used. *P < 
0.001 as compared to the controls (Groups I and II). ** P < 0.01 as compared to the controls (Groups I and II) and hepatotoxicity groups (Groups 
II and IV). *** P < 0.05 significant difference from the hepatotoxicity groups but not the control.
Table 3: Histological evaluation of liver tissues by light microscopy.
Group I Group II Group III Group IV Group V Group VI
Degeneration 0/10 0/10 10/10 10/10 6/10 6/10
Steatosis 0/10 0/10 7/10 7/10 3/10 2/10
Necrosis 0/10 0/10 7/10 8/10 2/10 2/10
Triaditis 0/10 0/10 8/10 8/10 0/10 0/10
Fibrosis 0/10 0/10 0/10 0/10 0/10 0/10
Regeneration 0/10 0/10 0/10 0/10 0/10 0/10
Constant doses of INH (50 mg/kg), RIF (100 mg/kg), PZA (350 mg/kg) and silymarin (200 mg/kg) were used. Group I: Control, Group II: Silymarin 
control, Group III: INH+RIF, Group IV: INH+RIF+PZA, Group V: INH+RIF+Silymarin, and Group VI: INH+RIF+PZA+Silymarin.Nutrition & Metabolism 2008, 5:18 http://www.nutritionandmetabolism.com/content/5/1/18
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flamatory cytokines and enhances apoptosis. In addition
to its hepatoprotective actions, silymarin is shown to be
effective in other organs including lung and brain; and to
inhibit tumor growth and promotion in several types of
cancer [18,30].
Conclusion
This study showed that silymarin has a significant protec-
tive action against the hepatotoxicity induced by the drugs
used in the treatment of tuberculosis. Although silymarin
has been used as a medical intervention for more than
2000 yr, there remains insufficient evidence to support or
refuse its use in patients with liver disease. High-quality,
placebo-controlled randomized trials need to be con-
ducted before silymarin or its constituents can be advo-
cated as a medicine for use in humans. Since no
significant toxicity of silymarin is reported in human stud-
ies, this plant extract can be used as a dietary supplement
by patients taking anti-tubercular medications.
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